Monopar Therapeutics Inc ( (MNPR) ) has shared an announcement.
Monopar Therapeutics Inc., a clinical-stage radiopharmaceutical company, presented promising human clinical dosimetry data for its novel uPAR-targeted radiopharmaceuticals MNPR-101-Zr and MNPR-101-Lu at the European Association of Nuclear Medicine 2024 Congress. The data highlights favorable organ safety profiles and encouraging tumor uptake, showcasing the potential of uPAR as a target in solid tumors. This development could signify a breakthrough in cancer treatment, catching the eye of investors and those interested in advancements within the stock and financial markets.
Find detailed analytics on MNPR stock on TipRanks’ Stock Analysis page.
